Aarkstore Enterprise—diabetes, Metabolic Syndrome And Cardiovascular Disease
Table of Contents :
1. Overview 8
1.1 Statement of Report 8
1.2 About this Report 8
1.3 Scope of the Report 9
1.4 Methodology 9
1.5 Executive Summary 11
2. Introduction 17
2.1 Demographics of Diabetes 17
2.1.1 Worldwide Diabetes 17
2.1.2 U.S. Diabetes 18
2.2 Economics of Diabetes 22
3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 28
3.1 Pre-Diabetes Syndrome 29
3.2 Metabolic Syndrome 29
3.3 Diabetes and Inflammation 32
3.4 Progression of Diabetes 32
3.5 Complications and Co-Morbidities in Type 2 Diabetes 33
3.6 Hypoglycemia and Treatment 38
3.7 Risk Factors and Diabetes 39
3.8 Cardiovascular Disease (CVD) Facts 40
4. Pharmaceutical Industry and the Anti-Diabetes Market 51
4.1 The Worldwide Pharmaceutical Industry 51
4.2 Total Diabetes Drug Market Size and Growth 58
4.2.1 Sales of Anti-Diabetic Drugs Continue to Rise 61
4.3 Epidemiology/Cost of Treatment 62
4.4 Diabetic Medications Overview 63
4.4.1 Recent Trends in Diabetic Drug Usage 63
4.4.2 Market Influence Factors 67
5. Non-Insulin Anti-Diabetes Products 69
5.1 Anti-Diabetic Drug Therapy Overview 69
5.1.1 Sulfonylureas 72
5.1.2 Meglitinides 73
5.1.3 Biguanides 73
5.1.4 Thiazolidinediones (TZDs) 74
5.1.5 a-Glucosidase Inhibitors 77
5.1.6 Incretin Mimetics/Glucagon-like Peptide (GLP-1) Analog 77
5.1.7 Amylin Analog 79
5.1.8 DPP-IV Inhibitors 79
5.1.9 Other Classes 81
5.1.10 Combination Therapy 81
5.2 Drivers and Trends 82
5.2.1 Market Share of Anti-Diabetic Drugs 82
5.2.2 Forecasts for Anti-Diabetic Drugs 82
5.2.3 Sales Forecast for the Global Diabetes Market 83
5.3 The Future 84
5.3.1 Practice Patterns 84
5.3.2 New Products in Pipeline 85
5.4 Anti-Diabetic Drug Patent Expiry 91
5.5 Regulatory Issues 91
6. Insulin 92
6.1 Insulin Markets 92
6.1.1 Major Players and Market Share 93
6.2 Insulin and Analogs 95
6.2.1 Rapid-Acting Insulin 95
6.2.2 Intermediate-Acting Insulin 97
6.2.3 Long-Acting Insulin/Ultra Long-Acting Insulin 97
6.2.4 Insulin Mixtures 99
6.3 Insulin Analogs 100
6.4 Non-Insulins in Development 100
6.5 Pipeline Insulin 101
6.6 Non-Invasive Insulin Delivery 101
6.6.1 Inhaled Insulin 101
6.6.1.1 Inhaled Insulin Overview 102
6.6.2 Oral Insulin 104
6.6.3 Transdermal Insulin 106
6.6.4 Oral Spray Insulin 108
6.7 Barriers for Non-Injected Insulin 109
6.8 Patient Potential for Non-Injected Insulin 109
6.9 Insulin Delivery Devices 109
6.9.1 Lancets and Lancing Devices 110
6.9.2 Insulin Pens 113
6.9.3 Injections Aids 117
6.9.3.1 Automatic Injectors 117
6.9.3.2 Syringe Magnifiers 118
6.9.3.3 Insulin Infusers 118
6.9.4 Insulin Jet Injectors 118
6.9.5 Insulin Pumps 119
6.9.5.1 External Insulin Pumps 119
6.9.5.2 Implantable Insulin Pumps 122
6.9.5.3 Insulin Pump Market Share 123
6.9.5.4 Drivers of Demand for Pumps 128
6.10 Market Forecasts for Insulin Administration Technologies 129
7. Emerging Anti-Diabetes Products 130
7.1 Projections for the Anti-Diabetes Drug Market 130
7.2 Artificial Pancreas 134
7.3 Insulin-Producing Cells 135
7.3.1 Cell Therapy Companies for Diabetes 135
7.4 Transplantation Procedures 137
7.4.1 Pancreatic Transplantation 138
7.4.1.1 Pancreatic Organ Transplantation 138
7.4.1.2 Allo-Islet Transplantation 138
7.4.1.3 Transplantation of Encapsulated Pancreatic Cells 139
7.4.1.4 Implantation of Genetically Engineered-Cells or Embryonic Stem Cells 139
7.4.2 Current Status 140
For more information please contact :
http://www.aarkstore.com/reports/Diabetes-Metabolic-Syndrome-and-Cardiovascular-Disease-1310.html
http://blogs.aarkstore.com/
From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
URL: www.aarkstore.com
